目的 建立盐酸安罗替尼胶囊药物利用评价（DUE）标准，并以加权TOPSIS法对盐酸安罗替尼胶囊用药的合理性进行评价，为临床合理性用药指导提供借鉴。方法 将盐酸安罗替尼胶囊说明书作为基础，并根据盐酸安罗替尼胶囊实际应用情况及相关的诊疗指南进行DUE标准的制定，并从医院信息系统（HIS）系统中采用随机的方法选取2022年1月—2024年8月以盐酸安罗替尼胶囊治疗的病历共180份，用加权TOPSIS法评价患者用药的合理性。结果 180份病例中相对接近成都（C_i）最高为1，最低为0.327，C_i≥80%有96例（53.33%），60%≤C_i＜80%有64例（35.56%），C_i＜60%有20例（11.11%）；用药不合理主要集中在适应证、用药监护、不良反应监测与处理。结论 以加权TOPSIS法对盐酸安罗替尼胶囊用药合理性进行评价，其评价结果能充分地反映其在临床应用中的合理性，且操作更方便、更直观地指导临床用药。

Objective To establish the drug utilization evaluation (DUE) criteria of Anrotinib Hydrochloride Capsules and evaluate the rationality of drug use of Anrotinib Hydrochloride Capsules based on the weighted TOPSIS method, so as to provide reference for clinical rationality of drug use guidance. Methods The instruction manual of Anrotinib Hydrochloride Capsules was used as the basis, and the DUE criteria were formulated according to the actual application of Anrotinib Hydrochloride Capsules and relevant diagnosis and treatment guidelines, and a total of 180 medical records treated with Anrotinib Hydrochloride Capsules during January 2022 to August 2024 were selected from HIS system using randomized method, and the reasonableness of the patient’s medication was evaluated using the weighted TOPSIS method. Results The highest C_i among 180 cases was 1, and the lowest was 0.327, and there were 96 cases (53.33%) with C_i ≥ 80%, 64 cases (35.56%) with 60% ≤ C_i < 80%, and 20 cases (11.11%) with C_i < 60%, the irrationality of medication use was mainly focused on indications, medication supervision, and the monitoring and treatment of adverse reactions. Conclusion The evaluation of the rationality of the medication of Anrotinib Hydrochloride Capsules by weighted TOPSIS method can fully reflect its rationality in clinical application, and the operation is more convenient and more intuitive to guide the clinical use of medication.

R979.1